nai_header

nai_headerbuttons

HomeAbout NAIManufacturingNewsInvestor RelationsContact UsFAQFAQ
   About Us
   Executive Team
   Board of Directors
   Bus. Development
   
   Manufacturing
   Global Operations
   North America
   Europe & Asia
   Investors
   Financial Data
   Annual Report
   Corp. Governance
   
 
   Certifications
   TGA Certification
   GMP Standards
   Publications
   News & Blog
   News
   CEO's Blog
   Industry Links
   

Natural Alternatives International, Inc. Announces Dismissal of All Product Liability Suits Involving CarnoSyn® Beta-Alanine

SAN MARCOS, Calif., Natural Alternatives International, Inc. (NAI) (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the plaintiffs in four product liability suits have dismissed all of their claims against NAI relating to CarnoSyn® beta-alanine.

NAI had been named as a co-defendant in cases involving a dietary supplement called Jack3d, which contains 1,3-dimethylylamylamine (also known as DMAA), which was formulated, made for and sold by USPLABS, LLC (USP). One of the ingredients used in the product was CarnoSyn® beta-alanine. NAI did not manufacture, formulate, package, distribute or sell the CarnoSyn® beta-alanine used by USP. NAI merely licensed the patents and trademark covering CarnoSyn® beta-alanine to USP.

Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "the product liability claims filed against the company were frivolous. There was absolutely no factual support for any suggestion that using beta-alanine as a dietary supplement, when taken as directed, was unsafe." LeDoux went on to say that "NAI's position has been completely vindicated. All of the claims against NAI were voluntarily dismissed by the plaintiffs, with prejudice, and without any payment by NAI. The benefits of using beta-alanine as a dietary supplement have been researched in over 20 peer reviewed scientific studies."

The four dismissed cases are: Sparling, et al. v. Doyle, et al., U.S. District Court for the Western District of Texas, No. 13-cv-323; Carolyne, et al. v. USPLABS, LLC, et al., Superior Court for Los Angeles County, California, No. BC 508212; Little, et al. v. USPLABS, LLC, et al., Superior Court for Los Angeles County, California, No. BC 508212; and Reed, et al. v. USPLABS, LLC, et al., U.S. District Court for the Southern District of California, No. 13-cv-3135. Claims against NAI in a fifth case, Ogbonna v. USPLABS, LLC, et al., U.S. District Court for the Western District of Texas, No. 13-cv-347, were previously dismissed by the Court.

NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at http://www.nai-online.com.

This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or investor@nai-online.com.